Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25641316 | 0.81 | HPGD (0.38) | LMNAHPGDSMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL25641315 | 0.77 | HPGD (0.45) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL16004765 | 0.74 | HPGD (0.38) | LMNAHPGDSMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL9934755 | 0.74 | HPGD (0.38) | LMNAHPGDSMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL25641317 | 0.72 | HPGD (0.47) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5400136 | 0.71 | HPGD (0.39) | LMNAHPGDSMN1; SMN2HSD11B1ALDH1A1 | |
| SCHEMBL23781724 | 0.68 | CYP2C19 (0.34) | LMNAHPGDSMN1; SMN2POLBKMT2A | |
| SCHEMBL7184444 | 0.68 | HPGD (0.42) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3821014 | 0.68 | HPGD (0.42) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL11598726 | 0.65 | HPGD (0.38) | LMNAHPGDSMN1; SMN2HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157548-A1 | USE OF CYCLOALIPHATIC DIOLS AS BIOCIDES | BASF SE (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157548-A1 | USE OF CYCLOALIPHATIC DIOLS AS BIOCIDES | DDT, DBH, GABBR1 | LMNA 4660/4885HPGD 1150/4885SMN1; SMN2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.